Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 3, 2010, Pages 401-404

  Minnock, Patricia ^a,b   Kirwan, John ^c   Veale, Douglas ^a,d   FitzGerald, Oliver ^a,d   Bresnihan, Barry ^a,d  

^a Our Lady's Hospice Ltd Dublin   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Fatigue; Outcome measure; Pain; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; FATIGUE; FEMALE; HUMAN; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RATING SCALE; SENSITIVITY ANALYSIS; ADOLESCENT; AGED; DRUG ANTAGONISM; MIDDLE AGED; PAIN; PILOT STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FATIGUE; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PILOT PROJECTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77956985815     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. GLADMAN DD, ANTONI C, MEASE P, CLEGG DO, NASH P: Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. 2): ii14-7.
2. LANGLEY RG, KRUEGER GG, GRIFFITHS CE: Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 (Suppl. 2): ii18-23 (discussion ii4-5).
3. MINNOCK P, BRESNIHAN B: Patients' priorities for improvement after 4 years. Arthritis Rheum 2004; 50: S471.
4. MINNOCK P, BRESNIHAN B: Fatigue is related to poor pain outcomes in women with established rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 707-8.
5. MEASE PJ, GLADMAN DD, KRUEGAR GG: Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA). Ann Rheum Dis 2005; 64 (Suppl. 2): ii1-2.
6. GLADMAN DD, MEASE PJ, STRAND V et al.: Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007; 34: 1167-70.
7. TAYLOR WJ: Preliminary identification of core domains for outcome studies in psoriatic arthritis using delphi methods. Ann Rheum Dis 2005; 64 (Suppl. 2): ii110-2.
8. GLADMAN DD, STRAND V, MEASE PJ, ANTONI C, NASH P, KAVANAUGH A: Omeract 7 psoriatic arthritis workshop: Synopsis. Ann Rheum Dis 2005; 64 (Suppl. 2): ii115-6.
9. BOERS M, BROOKS P, STRAND CV, TUGWELL P: The omeract filter for outcome measures in rheumatology. J Rheumatol 1998; 25: 198-9.
10. MOLL JM, WRIGHT V: Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
11. FELSON DT, ANDERSON JJ, BOERS M et al.: The american college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
12. WALTERS SJ, BRAZIER JE: What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003; 1: 4.
13. KERR A, HALL H, KOZUB S: Doing stastics with spss. London 2002.
14. KIRWAN JR, MINNOCK P, ADEBAJO A et al.: Patient perspective: Fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007; 34: 1174-7.
15. MINNOCK P, KIRWAN J, BRESNIHAN B: Fatigue is a reliable, sensitive, and unique outcome measure in rheumatoid arthritis. Rheumatology 2009 48: 1533-6.
16. GLADMAN DD, FAREWELL VT, WONG K, HUSTED J: Mortality studies in psoriatic arthritis: Results from a single outpatient center. Ii. Prognostic indicators for death. Arthritis Rheum 1998; 41: 1103-10.
17. CHANDRAN V, BHELLA S, SCHENTAG C, GLADMAN DD: Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007; 66: 936-9.
18. SCHENTAG C, CICHON J, MACKINNON A, GLADMAN D. UROWITZ M: Validation and normative data for the 0-10 point scale version of the fatigue severity scale (FSS). Arthritis Rheum 2000; 43.
19. WOLFE F, HAWLEY DJ, WILSON K: The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23: 1407-17.
20. PINCUS T, MACLEAN R, YAZICI Y, HARRINGTON JT: Quantitative measurement of patient status in the regular care of patients with rheumatic diseases over 25 years as a continuous quality improvement activity, rather than traditional research. Clin Exp Rheumatol 2007; 25: 69-81.
21. HUSTED JE, TOM BD, SCHENTAG CT, FAREWELL VT, GLADMAN DD: Occurrence and correlates of fatigue in psoriatic arthritis (PsA). Ann Rheum Dis 2008.
22. MEASE PJ, ANTONI CE, GLADMAN DD, TAYLOR WJ: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2): ii49-54.
23. HUSTED JA, GLADMAN DD, FAREWELL VT, COOK RJ: Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 151-8.
24. SANCHEZ ML, MCGWIN G, JR, DURAN S et al.: Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the lumina cohort (lxii): Use of the SF-6D. Clin Exp Rheumatol 2009; 27: 67-71.
25. TABACHNICK BG, LINDA S. FIDELL LS: Using multivariate statistics. Boston, Allyn & Bacon, 2001.